Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout

Gilead Sciences is set to acquire Ouro Medicines for $2.2bn, marking the company’s first move into the T-cell engager (TCE) space and a deepening of ties with long-term partner, Galapagos. Through this deal, the California-based big pharma company will hand over $1.68bn upfront, while pledging up to $500m in milestone payments to absorb the latter’s BCMA/CD3-targeting TCE, gamgertamig (OM336). The therapy is currently in clinical development for antibody-mediated orphan diseases such as immune thrombocyto ...